Tenax Therapeutics Inc

TENX

7.090USD

+0.075+1.07%

Close 11/05, 16:00（ET）Quotes delayed by 15 min

Tenax Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

75 / 407

Overall Ranking

194 / 4616

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 5 analysts

Strong Buy

Current Rating

21.000

Target Price

+199.36%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Tenax Therapeutics Inc Highlights

StrengthsRisks

Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 (IV), TNX-102 (subcutaneous) and TNX-103 (oral) levosimendan. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Overvalued

The company’s latest PE is 2.41, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 3.93M shares, increasing 24.32% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 22.29K shares of this stock.

The company's current financial score is 6.95, which is higher than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.95

Change

0



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

6.99

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.03

Key Metrics

Free cash flow

No Data

The company’s current valuation score is 8.79, which is higher than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is 2.41, which is 61.62% below the recent high of 3.90 and 378.91% above the recent low of -6.73.

Score

Industry at a Glance

Previous score

8.79

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 75/407

No Data

The company’s current earnings forecast score is 9.20, which is higher than the Biotechnology & Medical Research industry's average of 8.00. The average price target for Tenax Therapeutics Inc is 20.00, with a high of 30.00 and a low of 14.00.

Score

Industry at a Glance

Previous score

9.20

Change

0

Support & Resistance

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The company’s current price momentum score is 4.50, which is lower than the Biotechnology & Medical Research industry's average of 6.49. Sideways: Currently, the stock price is trading between the resistance level at 8.19 and the support level at 6.05, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

4.54

Change

-0.04

Support & Resistance

No Data

Institutional Confidence

Currency: USD Updated: 2025-11-05

Score

Industry at a Glance

Previous score

7.00

Change

0

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Ikarian Capital LLC

967.60K

--

RTW Investments L.P.

378.35K

--

The Lind Partners, LLC

375.00K

+435.71%

Dellora Investments LP

351.07K

--

BVF Partners L.P.

339.55K

--

Millennium Management LLC

233.71K

+777.77%

Vivo Capital, LLC

208.33K

--

Morgan Stanley & Co. LLC

174.75K

+48.30%



1

2



The company’s current risk assessment score is 3.80, which is higher than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 1.58. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.

Tenax Therapeutics Inc

TENX

6.88 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ascendis Pharma A/S

ASND

8.60 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

CytomX Therapeutics Inc

CTMX

8.57 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Insmed Inc

INSM

8.47 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Amicus Therapeutics Inc

FOLD

8.46 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Krystal Biotech Inc

KRYS

8.36 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment